

1-800-533-1710

PATIENT NAME			PATIENT NU	MBER		AGE	SEX	ACCESSION #
TESTING, 57123			L3MRNW37	769010		49	F	W3769010
ORDERING PHYSICIAN			CLIENT ORD	ER#				ACCOUNT # LIAISONS
COLLECTION RECEIVED		REPORT PR	INTED	SPECIMEN INFORM	ATION			
05/28/10 02:34 P	05/28/10 (	02:34 P	06/01/10	10:21 A	DATE OF BIRTH: 6/19/1960			
DATE TIME	DATE	TIME	DATE	TIME				
Test Client Attn: Mayo Liaisons 200 First Street SW								
Rochester, MN 55905 507-284-8202								

HI

TEST REQUESTED LO REF RANGE PERFORM SITE\*

## Arixtra Level (fondaparinux)

Arixtra Level 0.90 mg/L REF

Interpretive comments: Dosing protocols for Arixtra have been validated by empiric trials. The relationship between pharmacokinetic parameters and efficacy or safety (bleeding) has not been reported, nor have guidelines for target fondaparinux levels been published in the medical literature. Drug elimination half-life is approximately 17-21 hours in normal individuals, but is prolonged in patients with renal insufficiency. "Mean observed" drug levels are available from patients enrolled in clinical trials. In patients receiving daily injections of 2.5 mg (for DVT prophylaxis), the observed steady state mean peak level observed approximately 3 hours after injection was approximately 0.45 mg/L, with the observed minimum mean steady state plasma level of approximately 0.17 mg/L before the next dose. In patients receiving 5-10 mg Arixtra (for treatment of DVT or pulmonary embolism), the observed mean steady state peak level averaged approximately 1.23 mg/L approximately 3 hours after injection, with the observed minimum mean steady state plasma concentration at 0.58 mg/L before the next dose. (Data taken from prescribing inforation for Arixtra, and from GlaxoSmithKline informational materials.)

Test Performed by: BloodCenter of Wisconsin

638 N 18th St.

Milwaukee, WI 53201-2178

\* PERFORMING SITE

PATIENT NAME	ORDER STATUS	COLLECTION DATE AND TIME
TESTING, 57123	Final	05/28/10 02:34 P